AGTC and National Neurovision Research Institute Collaborate, Funding Research in two Genetic Retinal Diseases Combined Funds and Resources to be used to further demonstrate the AGTC’s AAV system’s ability to deliver sustainable treatments for human retinal diseases.
AGTC Expands its Clinical and Regulatory Expertise with Appointment of Jeffrey Chulay M.D. as Vice President of Chief Medical Officer July 9 2007 - AGTC (Applied Genetic Technologies Corporation), a privately held clinical stage gene therapy company, is pleased to announce that Dr.
AGTC Receives $2 Million Milestone from Genzyme After Successful Transfer of Novel Production Technology June 21, 2007 - AGTC (Applied Genetic Technologies Corporation), a privately held clinical stage gene therapy company, is pleased to announce that it has received a $2 million milestone payment
AGTC and JDRF announce partnership to develop gene therapy for diabetic eye disease May 16, 2006 – The Juvenile Diabetes Research Foundation has joined in a partnership with AGTC (Applied Genetic Technologies Corp.) and Genzyme Corporation to develop a gene therapy treatment to potentially prevent
AGTC Announces Initiation of New Phase 1 Clinical Trial February 23, 2006 - Applied Genetic Technologies Corporation (AGTC), a private clinical-stage biotechnology company, announced today the initiation of a Phase 1 clinical study to test the safety of AGTC-0106, its investigational gene therapy
Genzyme, AGTC Announce Gene Therapy Collaboration December 6, 2004 - Genzyme Corporation and Applied Genetic Technologies (AGTC), a private development-stage biotechnology company, announced today that they have entered into a research collaboration to jointly develop novel therapeutics involving
AGTC Raises $15,250,000 in Series A-1 Round December 1, 2003 - Applied Genetic Technologies Corporation, AGTC, a drug research company developing novel human therapeutics, announces that the Company has closed on a $15,250,000 Series A-1 Round led by InterWest Partners of Menlo Park, CA.